An observational study in IgG4-Related Disease, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2017-01-24.
Sponsored by Peking Union Medical College Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital — 7 open to participants now, 7 under way, 1 of them phase 3. Immunoglobulin G4-Related Disease · Peking Union Medical College Hospital.
Among the 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital, this one is the only one that started in 2016, is one of 4 observational ones, and was the 5th registered.
73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.
Browse Immunoglobulin G4-Related Disease studies →7 of the 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital are open now, in 1 country. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Ages 18–75
Peking Union Medical College Hospital
Ages 18+
By country, each count listing its studies:
Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 2 · Phase 4 1
First in 2012; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 900 is above the median of 112 across 20 observational studies indexed under Immunoglobulin G4-Related Disease.
Median enrollment 74 across the 11 interventional studies, 780 across the 4 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
1 of the studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03023371Peking Union Medical College HospitalNational Registry of IgG4-RD in China | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to establish a nation-wide cohort study of IgG4-related disease (IgG4-RD) in China.
Methods: All the patients fulfilling diagnostic criteria of IgG4-RD (2011) would be enrolled from multi-centers around China. A online database system has been established.
Endpoints: The primary endpoint is to investigate the clinical manifestations of Chinese IgG4-RD patients; the secondary endpoints including the demographic features,laboratory characteristics, immunological tests, imaging and pathological features, in addition, the treatment and prognosis of the disease.
This is a multicenter registry study of IgG4-RD patients. Newly diagnosed IgG4-RD patients will be recruited from allover the China. Inclusion criteria: patients with definite, probable, or possible IgG4-RD according to the 2011 comprehensive diagnostic criteria for IgG4-RD will be recruited. Exclusion criteria: patients with malignancy or other autoimmune diseases are excluded.
The data will be uploaded through the platform of Chinese Rheumatology Information Platform. Demographic data, initial symptoms, disease duration, history of allergy, and physical examination, organ involvements, laboratory findings, radiological and pathological results, as well as treatment, side effects will be recorded.
This study was approved by the Medical Ethics Committee of PUMCH (Beijing, China). All patients will signe informed consent.
Statistical Analysis: All parameters are described in the standard summary statistics, including mean, standard deviation, minimum, and maximum. All statistical analyses will be performed by SPSS.
Endpoints: The primary endpoint is to investigate the organ involvements of Chinese IgG4-RD patients. The secondary endpoints including the demographic features,laboratory characteristics, immunological tests, imaging and pathological features, in addition, the treatment and prognosis of the disease.
IgG4-RD patients around China
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Organ involvements of Chinese IgG4-RD patients
To calculate the percentage of organ involvements in at least 900 patients.
Time frame: 5 years
Response rate of glucocorticoids and immunosuppressants on IgG4-RD in China
Time frame: 5 years
Relapse rate of IgG4-RD patients in China
Time frame: 5 years
The correlation between baseline disease activities and relapse rate.
Time frame: 5 years
The incidence rate of tumor in IgG4 related disease patients in China.
Time frame: 5 years
Ten year survival rate of patients with IgG4 related disease in China.
Time frame: 10 years
The imaging features of involved organs.
Time frame: 3 years
The sensitivity and specificity of IgG4 positive plasma cells in pathological diagnosis of IgG4 related disease.
Time frame: 3 years
Plan to share: Yes
No publications or documents are linked to this record.
The record gives a start of Dec 2016, a primary completion of Dec 2026 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Immunoglobulin G4-Related Disease →
Peking Union Medical College Hospital →